Children with extreme hyperferritinemia are at risk of receiving more chemotherapy than necessary

References (1)

1. Çakan M, Aktay-Ayaz N, Gemici H, et al. Sustained hyperferritinemia in a child with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis-perforinopathy: case based review. Turk J Pediatr 2018; 60: 598-603. 2.Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013; CD001090. 3.Henter JI, Horne AC, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-131. 4.Demirkol D, Yildizdas D, Bayrakci B, et al; Turkish Secondary HLH/MAS Critical Care Study Group. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care 2012; 16: R52. 5.Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006; 148: 683-686. 6.Haytoglu Z, Yazici N, Erbay A. Secondary hemophagocytic lymphohistiocytosis: do we really need chemotherapeutics for all patients? J Pediatr Hematol Oncol 2017; 39: e106-e109.